PT. Cordlife Persada Attained its Fourth AABB Re-Accreditation for Cord Blood Banking and the First Accreditation for Somatic Cell Processing

Jakarta, Indonesia – **2025 December** – PT. Cordlife Persada is pleased to announce the successful completion of its fourth cycle of Association for the Advancement of Blood and Biotherapies (AABB) re-accreditation for cord blood banking, and for the first time, achieved AABB accreditation for somatic cell scope involving cord tissue. This expanded scope includes the processing, storage and distribution of cord lining and Wharton's Jelly.

In addition, PT. Cordlife Persada has attained AABB's Cellular Starting Material Qualification (CSMQ) - recognition granted only to AABB-accredited facilities. CSMQ highlights that the facility has the expertise, capacity, and quality system required to support cellular starting materials for advanced biotherapies. It confirms that our processes for donor qualification, processing and/or storage meet AABB's evidence-based standards.

The 2025 assessment was conducted in accordance with the 12th Edition of the AABB Standards for Cellular Therapy Services, which became effective in July 2025. The on-site audit was held on 11th and 12th November at PT. Cordlife Persada and was completed in collaboration with AABB-appointed assessors.

AABB accreditation is internationally recognised as a benchmark for excellence in cellular therapy. This milestone reinforces PT. Cordlife Persada's commitment to maintaining high standards of scientific, technical and operational performance, and provides assurance to families across Indonesia that their cord blood and cord tissue are handled in accordance with internationally accepted best practices.

This achievement reinforces PT. Cordlife Persada's position in supporting safe and reliable cellular therapy options for families in Indonesia and highlights the company's ongoing investment in future-ready healthcare solutions.

PT. Cordlife Persada remains vigilant in upholding the highest standards of service quality and safety, amid recent developments concerning Cordlife Singapore, specifically the stoppage of its activities related to the collection, testing, processing, and storage of new cord blood units by the Singapore Ministry of Health effective 26 November 2025.

We would like to assure all clients that the laboratory facilities and operations of PT. Cordlife Persada continue to function normally and are completely unaffected by the situation in Singapore. All cord blood units stored in our laboratory remain in good and secure condition. Our clients can directly verify the status of their stored cord blood units through the following link on our website: https://www.cordlife.co.id/en/sample_status_retrieval/search

PT Cordlife Persada functions as a separate operation from Cordlife Group within their respective countries. PT. Cordlife Persada's laboratory and storage facilities are overseen independently to meet the regulatory and quality standards set out by local Ministry of Health (DEPKES) as well as the

international accreditation body such as Association for the Advancement of Blood and Biotherapies (AABB) and International Organization for Standardization (ISO) certification.

PT. Cordlife Persada reaffirming its commitment to quality and international standards following the achievement of AABB re-accreditation for cord blood and AABB accreditation for somatic cell processing involving cord tissue in 2025.

About PT. Cordlife Persada

PT. Cordlife Persada is a majority-owned subsidiary of Cordlife Group Limited established in Indonesia since 2003. PT. Cordlife Persada is the first company to operate a full-fledged cord blood and cord tissue products processing and storage facilities in the country. In 2019, Cordlife Persada upgraded to a new facility located in Central Jakarta with a storage capacity for up to 70,000 stem cell units. This facility is currently the largest in Indonesia and the first and only to be accredited by AABB. For more information, visit www.cordlife.co.id.